NCT01601808 2025-03-13
ViP
University of Liverpool
Phase 2 Completed
Clinical Trials
53 trialsNCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT00537095 2024-04-19
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
Sanofi
Phase 2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT01934335 2021-11-01
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
University of Iowa
Phase 2 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01414426 2021-01-14
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
University of Chicago
Phase 2 Completed
NCT01823068 2020-12-07
Vandetanib in Advanced NSCLC With RET Rearrangement
Samsung Medical Center
Phase 2 Completed
NCT02015065 2020-03-30
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT00613626 2020-02-11
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT01191892 2019-05-16
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
Phase 2 Completed
NCT00459121 2019-03-26
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00566995 2018-10-30
Phase II Study of Vandetanib in Individuals With Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00880334 2018-09-18
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00687297 2018-05-30
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
PrECOG, LLC.
Phase 2 Completed
NCT00098345 2018-05-07
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Sanofi
Phase 2 Completed
NCT00500292 2018-01-25
A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Sanofi
Phase 2 Completed
NCT00481845 2017-02-07
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Stanford University
Phase 2 Terminated
NCT00358956 2017-01-30
A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Sanofi
Phase 2 Completed
NCT00686036 2016-12-21
ZENITH
Sanofi
Phase 2 Terminated
NCT00872989 2016-12-19
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00659438 2016-12-05
Efficacy and Safety of Zactimaâ„¢ in Patients With Castration-refractory Metastatic Prostate Cancer
Sanofi
Phase 2 Completed
NCT00752986 2016-12-05
ZACFAST
Sanofi
Phase 2 Terminated
NCT00753714 2016-10-17
ZELIG
Sanofi
Phase 2 Completed
NCT00508001 2016-10-10
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
Sanofi
Phase 2 Completed
NCT00597116 2016-10-10
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Sanofi
Phase 2 Terminated
NCT00753675 2016-10-10
VANGOGH
Sanofi
Phase 2 Completed
NCT00777179 2016-10-10
Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
Sanofi
Phase 2 Completed
NCT00454116 2016-10-07
A Phase II, Double Blind Study of 2 Doses of ZACTIMAâ„¢(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Sanofi
Phase 2 Completed
NCT00498797 2016-10-07
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00494481 2016-09-30
E3 Breast Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00047840 2016-08-25
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
Sanofi
Phase 2 Completed
NCT00071188 2016-08-25
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00252746 2016-08-25
ZD6474 Phase IIa Dose Finding Multicentre Study
Sanofi
Phase 2 Completed
NCT00034918 2016-08-24
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
Sanofi
Phase 2 Completed
NCT00047788 2016-08-24
Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
Sanofi
Phase 2 Completed
NCT00059722 2016-08-24
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
Sanofi
Phase 2 Completed
NCT00066313 2016-08-24
ZD6474 in Treating Patients With Small Cell Lung Cancer
Sanofi
Phase 2 Completed
NCT00290537 2016-05-19
Phase II Study of ZD6474 in Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00995007 2016-03-29
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00402896 2016-03-09
Malignant Pleural Effusion With ZD6474
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00720083 2015-11-17
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 2 Terminated
NCT01372813 2015-10-23
Vandetanib to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02530411 2015-08-21
FURVA
Velindre NHS Trust
Phase 2 Unknown
NCT00410189 2015-03-23
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00683787 2015-01-08
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00811369 2013-11-18
ZAMBONEY
Ontario Clinical Oncology Group (OCOG)
Phase 2 Completed